Today: November 24, 2017, 2:01 pm

Bispecifics: From Discovery to First in Human

Bispecifics: From Discovery to First in Human
SMi is proud to announce that Peter Bach, Director from BioPharmaLogic Ltd, will be hosting the Bispecifics: From Discovery to First in Human masterclass taking place on the 13th January 2015 in Central London 2014-08-14 17:41:58
This full-day Masterclass will provide the top view for all disciplines and functions including discovery, manufacturing, nonclinical, regulatory and clinical to provide each with the challenges faced by the other disciplines. The masterclass aims to cover the most important aspects that should be part of the “big picture” to file an IND.

Progressing Bispecifics depends on early strategic clarity, and understanding what is possible by using different approaches in different regions of the world. The Masterclass will examine these options to help get the quickest First-Time in Human Study (FTIH) that is risk managed. It will then “back-fill” how these objectives can be reached and how to deal with the unexpected. Each of the steps required to provide an agency with a credible manufacturing package, demonstrable efficacy and safety assessment, supporting a risk management plan for a FTIH study.

Attendees will hear from Peter H Bach, as he examines options to help get the quickest First-Time in Human Study (FTIH) that is risk managed. He will then “back-fill” how these objectives can be reached and how to deal with the unexpected.

For further details please visit:
Alternatively contact Fateja Begum on +44 (0) 207 827 6184 or email at


About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries. More information can be found at

About BioPharmaLogic Ltd:
BioPharmaLogic Ltd works with multidisciplinary teams to expedite nonclinical development to enable first-time-in-humans and proof of concept. They deliver challenging milestones that supported start-ups, SMEs, mid-Cap and global Biopharmaceutical companies, especially in the development of biosimilars and next generation Bispecifics.

Press Information
SMi Group Ltd
2nd Floor South, Harling House
47-51 Great Suffolk Street
United Kingdom

Teri Arri
Marketing Executive
+44 (0) 20 7827 6162

Published by
Daniel Lee

# 384 Words
Related Articles
More From Science
MyScienceWork announces collaboration with The French Institute [..]
Virginie Simon, CEO of MyScienceWork said: “We are very proud to work with the international renowned institution INED and [..]
The game algorithm that could improve materials [..]
Tsukuba, Japan, Aug 23, 2017 - (ACN Newswire) - Designing advanced materials is a complex process, with many potential combinations [..]
SpectralWorks Limited and Mestrelab Research SL announce [..]
The software companies SpectralWorks Ltd (SpectralWorks) and Mestrelab Research SL (Mestrelab) announced today that they have [..]
Mangroves vital for environmental decontamination
Selangor, Malaysia, Aug 5, 2017 - (ACN Newswire) - Grey mangrove trees, Avicennia marina, filter heavy metals out of the [..]
Who learns foreign language better - introverts [..]
Extravert Chinese students learning English as a second language are likely to perform better in speaking and reading, but less [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.